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Objective: To evaluate the physical compatibility and chemical stability
of mixtures of magnesium sulphate and lidocaine in order to
determine the feasibility of manufacturing a preﬁlled syringe
combining these two drugs for use as an intramuscular (IM)
loading dose for eclampsia prevention and/or treatment. This ready-
to-use mixture will provide a more tolerable and accessible route of
administration appropriate for widespread use.
Methods: Physical compatibility (pH, colour, and formation of
precipitate) and chemical stability (maintaining > 90% of initial
concentrations) of mixtures of MgSO4, using both commercially
available MgSO4 (50%) and MgSO4 reconstituted from salt (61%),
with lidocaine hydrochloride (2%) were evaluated every 14 days
over six months. The concentration of lidocaine was determined by
a stability indicating high performance liquid chromatographic
method, while the concentration of magnesium was determined by
an automated chemistry analyzer.
Results: No changes in pH, color or precipitates were observed for up
to 6 months. The 95% conﬁdence interval of the slope of the curve
relating concentration to time, determined by linear regression,
indicated that only the admixtures of commercially-available
magnesium sulfate and lidocaine as well as the 61% magnesium
sulfate solution (reconstituted from salt) maintained at least 90% of
the initial concentration of both drugs at 25C and 40C at 6 months.Key Words: Preeclampsia, eclampsia, magnesium sulphate,
chemical stability
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936 l OCTOBER JOGC OCTOBRE 2016Conclusions: Commercially available MgSO4 and lidocaine
hydrochloride, when combined, are stable in a pre-ﬁlled syringe for
at least six months in high heat and humidity conditions. This ﬁnding
represents the ﬁrst step in improving the administration of
magnesium sulphate in the treatment and prevention of eclampsia
in under-resourced settings.
Résumé
Objectif : Évaluer la compatibilité physique et la stabilité chimique des
mélanges du sulfate de magnésium et de lidocaïne, aﬁn de
déterminer la possibilité de fabriquer une seringue préremplie de
ces deux médicaments, aux ﬁns d’utilisation comme dose de
charge, par voie intramusculaire (IM). Ce mélange prêt à l’utilisation
permettra d’avoir une voie d’administration plus tolérable et plus
accessible, dont l’usage pourrait être généralisé.
Méthodes : La compatibilité physique (pH, couleur, et formation de
précipité), ainsi que la stabilité chimique (taux des concentrations
initiales maintien à plus de 90 %) d’une combinaison de MgSO4,
obtenu à partir de MgSO4 (50%) commercialisé et de MgSO4
reconstitué à partir du sel (61 %), et de chlorhydrate de lidocaïne
(2 %) ont été évaluées tous les 14 jours, pendant six mois. La
concentration de lidocaïne a été déterminée à l’aide de la
chromatographie liquide à haute performance, tandis que la
concentration de magnésium a été déterminée à l’aide d’un
analyseur chimique automatisé.
Résultats : Aucun changement du pH, de la couleur ou des précipités
n’a été observé pendant une période allant jusqu’à 6 mois.
L’intervalle de conﬁance à 95 % de la pente de la courbe reliant la
concentration et le temps, déterminée par la régression linéaire, a
indiqué que seuls les mélanges de sulfate de magnésium et de
lidocaïne commercialisés, ainsi que la solution de sulfate de
magnésium à 61 % (reconstitué à partir du sel) ont gardé au moins
90 % de la concentration initiale des deux médicaments, à 25C et
40C, après 6 mois.
Magnocaine: Physical Compatibility and Chemical Stability of MgSO4 and Lidocaine Hydrochloride in Preﬁlled SyringesConclusion : Lorsqu’ils sont combinés dans une seringue préremplie,
le MgSO4 commercialisé et le chlorhydrate de lidocaïne restent
stables, pendant six mois au moins, dans un milieu très chaud et
très humide. Ce résultat constitue un premier pas vers l’amélioration
de l’administration du sulfate de magnésium pour le traitement et la
prévention de l’éclampsie dans des milieux défavorisés.
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ypertensive disorders of pregnancy affect approxi-Hmately 10% of all pregnant women around the
world1,2; 2% to 8% of pregnant women with hypertension
will develop preeclampsia and risk progressing to
eclampsia. This multisystem disorder leads not only to
placental insufﬁciency and resultant neonatal morbidity
but also to maternal organ dysfunction, making it a
major cause of maternal morbidity and mortality
worldwide.3
The treatment of choice for both the prevention and the
treatment of eclampsia is magnesium sulphate. The use of
magnesium sulphate, compared with placebo or no anti-
convulsant, is associated with halving the risk of women
with preeclampsia progressing to eclampsia.4,5 In addition,
magnesium sulphate is the anticonvulsant of choice for
women with eclampsia,6 and is proven to be more effective
than diazepam,7 phenytoin,8 or lytic cocktail.9
A recent Cochrane review showed that there is little reliable
evidence from randomized trials assessing the minimum
effective dose, the comparative effects of alternative routes
of administration, or the ideal duration of therapy.10ABBREVIATIONS
CL2 commercially available lidocaine HCl 2%
CM50 commercially available magnesium sulphate 50%
CM50CL2 commercially available magnesium sulphate 50%
combined with lidocaine
HPLC high performance liquid chromatography
IM intramuscular
IS internal standard
IV intravenous
MS magnesium sulphate heptahydrate USP dissolved in SWI
MSCL2 magnesium sulphate heptahydrate USP dissolved in SWI
combined with lidocaine HCl 2%
SWI sterile water for injection
USP United States PharmacopeiaCurrently, the most widely used and studied regimens for
administration of magnesium sulphate are those of
Pritchard (10 g, injecting 5 g intramuscularly into each
buttock, combined with a 4 g intravenous loading dose and
a 5 g IM maintenance dose every 4 hours)11,12 and Zuspan
(4 g IV loading dose then maintenance of 1g/h IV
infusion).13 Regardless of the regimen used, the WHO
advises using any dose of magnesium sulphate in
women with preeclampsia, stating that “the patient (is)
likely to be better off with only the loading dose than
without it.”14
This recommendation is important; despite being widely
used, IV regimens present difﬁculties in less developed
countries in which resources and support for IV adminis-
tration are not routinely available. The IM route is logisti-
cally an easier route of administration and does not require
continuous monitoring. IM administration is also more
appropriate in health centres that are staffed by lay health
workers with limited training. However, IM injection also
has potential disadvantages, especially pain and infection at
the injection site. The pain experienced is in large part due
to the 10 mL volume of solution that must be injected into
each buttock to administer the loading dose. Using either a
smaller volume for injection (a more concentrated solution)
or combining magnesium sulphate with a local anaesthetic
agent, such as lidocaine, prior to injection would presum-
ably ease this pain. However, to our knowledge, the stability
of neither a more concentrated solution of magnesium
sulphate nor the combination of magnesium sulphate with
lidocaine hydrochloride has been investigated.
The purpose of this study was to evaluate the physical
compatibility and chemical stability of the combination of
magnesium sulphate and lidocaine hydrochloride, com-
pounded fromUnited States Pharmacopeia solution and salt
and stored in polypropylene syringes at room temperature
(25C) and at high heat (40C) for up to 168 days. Estab-
lishing these characteristics is critical for determining the
feasibility of manufacturing a preﬁlled syringe combining
these two drugs as an IM loading dose for eclampsia pre-
vention and/or treatment in under-resourced settings.
METHODS
Preparation of Magnesium Sulphate and Lidocaine
and Set Up
Stock solutions of magnesium sulphate, lidocaine, and
magnesium sulphate-lidocaine mix were prepared, ﬁltered,
placed in sterile VIAFLEX bags (Baxter Corp., Mississauga
ON), and aliquoted into 5 mL sterile BD Luer-Lok plastic
syringes (VWR International LLC, Mississauga ON). The
syringes (Kendall Pharmaceuticals, Charlotte, NC) wereOCTOBER JOGC OCTOBRE 2016 l 937
Table 1. Products and controls prepared
Product/Control Components
Conc
MgSO4
Total
Volume
Experimental
Products
CM50CL2 10 mL commercially-available
MgSO4 (50%)
AND
1 mL Lidocaine HCl (2%)
45.5% 10 mL
MSCL2 5 g MgSO4 salt dissolved in
5.3 mL sterile water for
injection
AND
1 mL Lidocaine HCl (2%)
54% 9.2 mL
Controls
MS 5 g MgSO4 salt dissolved in
5.3 mL sterile water for
injection
61% 8.2 mL
CM50 10 mL commercially-available
MgSO4 (50%)
50% 10 mL
CL2 1 mL Lidocaine HCl (2%) N/A 1 mL
DRUGS IN PREGNANCYcapped. As outlined in Appendix 1, one half of the syringes
(225 syringes) were stored in a lightless container at 25C
and the remainder were stored in a lightless humidiﬁed
incubator set at 40C.
The concentrations and volumes of each mixture are
summarized in Table 1. A mixture of 540 mL of
commercially available magnesium sulphate 50% USP
(Pharmaceutical Partners of Canada Inc., Richmond Hill
ON) and 54 mL of lidocaine HCl 2% (Alveda Pharma-
ceuticals Inc., Toronto ON) was prepared and labelled as
CM50CL2. Magnesium sulphate heptahydrate USP (610 g)
(Medisca Pharmaceuticals Inc., Richmond BC) was
dissolved in sterile water for injection (Baxter Corp., Mis-
sissauga ON) to a volume of 1 L and labelled as MS.
Magnesium sulphate heptahydrate USP (543.5 g) was
dissolved in SWI. Lidocaine HCl 2% (108.7 mL)
was added to the solution. The volume of the solution was
adjusted to 1 L with SWI; the sample was labelled as
MSCL2. Commercially available magnesium sulphate 50%
USP, labelled as CM50, and commercially available lido-
caine HCl 2%, labelled as CL2, were used as controls.
Physical Compatibility
Physical characteristics of the solutions were evaluated at
the time of preparation and at 14-day intervals up to 168
days. At each time point, three syringes of each group were
examined visually for obvious changes in colour and pre-
cipitation. The contents of the 5 mL syringes were trans-
ferred to conical tubes to determine pH. The model 800
pH meter (VWR International LLC, Mississauga ON) was
calibrated at the beginning of each session using938 l OCTOBER JOGC OCTOBRE 2016commercially available standards (pH 7.0 and 4.00, Fisher
Scientiﬁc Co., Whitby ON). Immediately following the
physical observations, a 1.8 mL aliquot from each sample
was transferred to a polypropylene CryoVial (VWR In-
ternational LLC Mississauga ON) and stored at 85C
until analysis.
CHEMICAL STABILITY
Chemistry analyzer
Magnesium assay part no. 445360 and UniCel DxC 600i
Synchron Access clinical system (Beckman Coulter Inc.,
Brea, CA) was used to determine the concentration of
magnesium. A detailed description of the assay has been
previously published15 and is outlined in Appendix 2. The
analysis was performed in triplicate with results reported as
means.
High performance liquid chromatography
instrumentation
Full details of HPLC methodology are provided in
Appendix 2.16,17
Statistical Analysis
Mean, standard deviation, coefﬁcient of variation, and
accuracy were calculated for all of the samples analyzed.
For each study day, the percentage of the remaining con-
centration of magnesium sulphate and lidocaine was
calculated. The percentage remaining at the end of the
study period was calculated from the concentration on the
last day (day 168) as determined by linear regression and
the concentration observed on day 0, according to the
following formula: (concentration on day 168/concentra-
tion on day 0)  100%. The 95% conﬁdence interval of
the amount remaining on day 168 was calculated from the
lower limit of the 95% CI of the slope of the curve relating
concentration to time according to the following formula:
lower limit of the 95% CI of the concentration on day 168/
concentration on day 0  100%. Stability was deﬁned as
maintenance of at least 90% of the initial concentrations.
RESULTS
Physical Stability
After 168 days, there were no visible signs of particulate
matter in any of the syringes. Each solution remained
colourless over the course of the study. There were no
major changes in pH for all of the clear solutions. The
mean (± standard deviation) pH values were 5.69 ± 0.118
and 5.52 ± 0.127 for CL2 stored at 250C and 400C,
respectively; 5.58 ± 0.368 and 5.22 ± 0.483 for MSCL2
stored at 25C and 40C, respectively; 5.60 ± 0.396 and
5.22 ± 0.380 for CM50CL2 stored at 25C and 40C,
Figure 1. Chemical stability of CM50CL2 Figure 2. Chemical stability of MSCL2
Figure 3. Chemical stability of MS
Magnocaine: Physical Compatibility and Chemical Stability of MgSO4 and Lidocaine Hydrochloride in Preﬁlled Syringesrespectively; 7.52 ± 0.397 and 7.48 ± 0.25 for MS stored at
25C and 40C, respectively; and 6.60 ± 0.217 and 6.75 ±
0.216 for CM50 stored at 25C and 40C, respectively.
Chemical Stability
The analysis of the peak ratio of lidocaine to dexametha-
sone (the internal standard) versus the concentration of
each lidocaine standard demonstrated linearity over the
range of concentrations with coefﬁcient of determination
(r2)  0.999 (n ¼ 4). The intra-day and inter-day
coefﬁcients of variation were within acceptable limits of
0.94% and 1.64 % at 0.1 mg/mL, 0.33% and 0.95% at 0.25
mg/mL, 0.55% and 0.58% at 0.4 mg/mL, and 0.54% and
0.54% at 0.6 mg/mL, respectively. The intra-day and inter-
day accuracy were also within acceptable limits at 98.7% ±
1.13% and 99.2% ± 0.79% at 0.1 mg/mL, 98.8% ± 1.03%
and 98.8% ± 1.22% at 0.25 mg/mL, 99.2% ± 0.32% and
99.2% ± 0.80% at 0.4 mg/mL, and 99.6% ± 0.40% and
99.6% ± 0.39% at 0.8 mg/mL, respectively.
The retention times were 3.8 minutes for lidocaine and 5.8
minutes for the IS dexamethasone. None of the peaks
generated by forced degradation interfered with the peaks
of interest (lidocaine or the IS dexamethasone). When CL2
was force degraded, the lidocaine peaks were decreased by
28.6% and 46.3% when exposed to NaOH at 25C and
100C, respectively; by 18.3% and 14.9% when exposed to
HCl at 25C and 100C, respectively; and by 85.0% and
97.6% when exposed to 30% H2O2 at 25C and 100C,
respectively. The forced degradation decreased the MSCL2
lidocaine peaks by 55.7% and 74.9% when exposed to
NaOH at 25C and 100C, respectively; by 60.4% and
70.7% when exposed to HCl at 25C and 100C, respec-
tively; and by 84.2% and 97.1% when exposed to H2O2 at
25C and 100C, respectively. Finally, the CM50CL2 lido-
caine peaks were decreased by 22.8% and 60.2% when
exposed to NaOH at 25C and 100C, respectively; by
14.7% and 19.7% when exposed to HCl at 25C and100C, respectively; and by 97.5% and 94.7% when
exposed to H2O2 at 25C and 100C, respectively. Thus,
the HPLC method was deemed capable of indicating
stability.
The HPLC analysis showed that all preparations stored at
25C or 40C maintained at least 90% of their original
lidocaine concentration for 168 days (Figures 1, 2, and 3).
The lower limit of the 95% conﬁdence interval relating
concentration to time determined by linear regression
indicated that the lidocaine and lidocaine-magnesium sul-
phate solutions stored at 25C maintained 97.5% (CL2),
96.4% (MSCL2), and 95.7% (CM50CL2), respectively, of
their initial concentration throughout the study period (168
days). The solutions stored at 40C maintained 95.0%
(CL2), 98.6% (MSCL2), and 95.2% (CM50CL2), respec-
tively, of their initial concentrations throughout the study
period (Tables 2, 3, and 4).
The UniCel DxC 600i Synchron Access clinical system was
tested for interference by analyzing the control CL2 sam-
ples stored for up to 168 days at both 25C and 40C. No
magnesium was detected in any of the lidocaine samples (in
which the lower analytical range was 0.4 mmol/L). Simi-
larly, when normal saline stored in polypropylene syringes
was run through the chemical analyzer, no magnesium wasOCTOBER JOGC OCTOBRE 2016 l 939
Table 2. Percentage of initial concentration of commercially available magnesium sulphate and commercially available
lidocaine hydrochloride remaining after 168 days of storage at 25C and 40C (CM50CL2)
Variable
25C 40C
Magnesium sulphate
(mmol/L)
Lidocaine hydrochloride
(mg/mL)
Magnesium sulphate
(mmol/L)
Lidocaine hydrochloride
(mg/mL)
Initial concentration 1861 1635 1861 1635
Study Day
1 101.2 99.9 102.0 99.4
2 101.5 98.9 101.9 96.5
3 101.6 98.6 102.1 97.1
7 101.0 97.9 100.6 97.3
14 102.1 99.0 100.5 98.1
28 101.6 98.1 102.4 98.3
42 101.9 99.6 102.7 99.1
56 98.4 99.8 102.7 99.6
70 99.8 95.9 100.5 95.4
84 99.7 98.8 99.5 98.1
98 96.9 95.6 94.9 96.3
112 95.4 96.8 96.0 94.4
126 97.8 94.6 99.7 94.1
140 99.9 97.7 99.0 98.9
154 94.3 98.2 96.7 95.5
168 98.1 98.1 93.2 97.6
Estimated % remaining on day 168 95.0 97.7 93.9 97.7
Lower 95% CI for % remaining 93.4 95.7 92.0 95.2
DRUGS IN PREGNANCYdetected, thereby ruling out leaching of magnesium from
the syringes. Finally, when a known concentration of
magnesium sulphate was added to the samples of lidocaine
and measured for magnesium (method of standard addi-
tion), no deviations from the expected concentrations were
found, thus ruling out negative interference.
The magnesium assay showed that only the CM50CL2
maintained more than 90% of the initial concentration of
magnesium sulphate in both storage conditions for 168
days (Table 2 and Figure 1). The reconstituted magnesium
sulphate salt alone also retained more than 90% of its initial
concentration at both temperatures (Table 5 and Figure 3)
but when combined with commercially available lidocaine,
was only chemically stable at 40C (Table 3 and Figure 2).
The lower limit of the 95% conﬁdence interval relating
concentration to time (determined by linear regression)
indicated that magnesium and magnesium-lidocaine solu-
tions stored at 25C maintained 93.4% (CM50CL2), 80.0%
(MSCL2), 93.1% (CM50), and 93.3% (MS), respectively, of
their initial concentration throughout the study period. The
solutions stored at 40C maintained 92.0% (CM50CL2),
99.6% (MSCL2), 89% (CM50), and 94.3% (MS), respec-
tively, of their initial concentrations throughout the study
(Tables 2, 3, 5, and 6).940 l OCTOBER JOGC OCTOBRE 2016DISCUSSION
This study has shown that commercially available magne-
sium sulphate and lidocaine hydrochloride, when com-
bined, are stable in a preﬁlled syringe for at least 168 days
at 25C and in conditions of high heat and humidity. This
ﬁnding represents the ﬁrst step in improving the admin-
istration of magnesium sulphate in the treatment and
prevention of eclampsia.
Although it is well established that magnesium sulphate
reduces morbidity and mortality associated with pre-
eclampsia and eclampsia, it is not used regularly in some
resource-limited settings. In a multi-country survey of
maternal and newborn health conducted by the WHO,
only 85.7% of women with eclampsia received the life-
saving drug magnesium sulphate.18 Identifying and elimi-
nating barriers remains an important priority for clinicians
and policy makers.
IV regimens for drug administration are difﬁcult to
establish and maintain in less developed countries where
the necessary resources and technical support may not be
available. In addition, the majority of care in areas remote
from health centres is provided by community health care
providers who have little formal training. IM injection is a
Table 3. Percentage of initial concentration of reconstituted magnesium sulphate salt and commercially available
lidocaine hydrochloride remaining after 168 days of storage at 25C and 40C (MSCL2)
Variable
25C 40C
Magnesium sulphate
(mmol/L)
Lidocaine hydrochloride
(mg/mL)
Magnesium sulphate
(mmol/L)
Lidocaine hydrochloride
(mg/mL)
Initial concentration 2227 1863 2227 1863
Study Day
1 100.0 95.9 100.9 98.4
2 98.6 95.5 99.9 95.7
3 99.6 94.9 100.0 95.7
7 99.1 95.7 97.1 95.3
14 99.6 94.8 99.3 96.9
28 99.1 98.3 99.0 95.1
42 99.6 96.5 99.9 96.2
56 99.9 97.3 97.4 95.0
70 100.9 96.7 100.0 95.1
84 98.1 93.8 98.1 93.1
98 92.7 96.5 93.1 99.8
112 101.5 95.6 100.8 95.5
126 99.2 95.0 96.1 96.5
140 95.0 94.9 103.0 95.8
154 79.0 95.4 a 94.7
168 75.9 95.6 111.8 95.3
Estimated % remaining on day 168 85.9 98.5 104.2 99.6
Lower 95% CI for % remaining 80.0 96.4 99.6 98.6
aInsufﬁcient sample to measure concentration.
Magnocaine: Physical Compatibility and Chemical Stability of MgSO4 and Lidocaine Hydrochloride in Preﬁlled Syringesvalidated mode of administration of magnesium sulphate
used in both the Magpie5 and the Collaborative Eclampsia6
Trials and is an easier route of administration than IV
administration. The injection not only requires less trainingTable 4. Percentage of initial concentration of lidocaine
hydrochloride remaining after 168 days of storage at
25C and 40C (CL2)
Variable
25C 40C
Lidocaine
hydrochloride
(mg/mL)
Lidocaine
hydrochloride
(mg/mL)
Initial concentration 21 841 21 841
Study Day
14 97.9 95.4
28 97.5 100.0
56 95.7 98.4
84 98.7 99.9
112 98.8 99.0
140 100.4 96.2
168 99.0 99.6
Estimated % remaining
on day 168
101.3 100.0
Lower 95% CI for %
remaining
97.5 95.2to enable safe administration but also does not require the
same level of monitoring or cumbersome supplies required
by IV administration (which requires continuous moni-
toring). These factors are critical when the IM injection is
given in a remote setting or when it is given in units in
which the number of patients exceeds the number of
available health care professionals, and they permit wider
use of the medication. Furthermore, providing an injection
of the IM loading dose prior to transfer of a patient pre-
vents any delay in patients receiving this lifesaving
treatment.
The disadvantage of IM administration is the pain asso-
ciated with injection. In several studies evaluating pain with
IM injection of benzathine penicillin and ceftriaxone,
reported pain was greatly reduced by combining the anti-
biotic with a local anaesthetic agent such as lidocaine.19e22
Very few studies of the use of magnesium sulphate in
preeclampsia and eclampsia have described lidocaine being
added to relieve the pain of the IM injection. In those that
have described doing so, 1 mL of either a 1% or 2%
lidocaine hydrochloride solution was drawn up in the same
syringe as magnesium sulphate immediately before
administering the IM injection.11,23e25 This extra step
complicates the dosing of magnesium sulphate, particularlyOCTOBER JOGC OCTOBRE 2016 l 941
Table 5. Percentage of initial concentration of
reconstituted magnesium sulphate salt remaining after
168 days of storage at 25C and 40C (MS)
Variable
25C 40C
Magnesium
sulphate
(mmol/L)
Magnesium
sulphate
(mmol/L)
Initial concentration 2461 2461
Study Day
1 97.3 97.1
2 100.9 100.3
3 97.6 100.1
7 101.5 99.1
14 101.6 100.7
28 100.0 103.7
42 100.4 101.4
56 96.1 102.6
70 101.4 103.1
84 98.4 106.9
98 96.1 98.1
112 96.1 92.8
126 97.4 100.2
140 95.3 98.0
154 95.0 98.6
168 95.9 97.5
Estimated % remaining
on day 168
95.2 97.6
Lower 95% CI for % remaining 93.3 94.3
Table 6. Percentage of initial concentration of
commercially available magnesium sulphate remaining
after 168 days of storage at 25C and 40C (CM50)
Variable
25C 40C
Magnesium
sulphate
(mmol/L)
Magnesium
sulphate
(mmol/L)
Initial concentration 2003 2003
Study Day
14 103.0 106.6
28 102.4 102.0
56 103.7 103.2
84 103.7 105.2
112 97.1 95.3
140 99.8 102.6
168 99.3 96.1
Estimated % remaining on day
168
96.7 94.5
Lower 95% CI for % remaining 93.1 89.0
DRUGS IN PREGNANCYin the case of a minimally trained health care provider;
withdrawing two solutions from two different vials may
lead to dosing errors, an increased risk of contamination,
and inadvertent needle stick injuries.
Concern about the side effects caused by magnesium sul-
phate is another reason cited for practitioners’ reluctance to
use the drug. Although administration of magnesium sul-
phate is commonly associated with a feeling of warmth,
ﬂushing, and nausea and vomiting, toxic side effects leading
to central nervous system and/or respiratory depression are
uncommon. In a review of 24 studies of a total of 9556
women treated with magnesium sulphate for eclampsia
prevention or treatment in low to middle income countries,
side effects of concern were rare; they included absent
patellar reﬂexes (1.6%), respiratory depression (1.3%), and
the need to use calcium gluconate to counteract the effects of
magnesium sulphate (0.2%).26 These were comparable to
the 1% incidence of adverse side effects in the Magpie study,
which had the largest study population of over 5000
women.5 In fact, McDonald et al. conducted a systematic
review of “real-world” use of magnesium sulphate and
found that the maternal beneﬁts far outweighed the small
risk of magnesium toxicity.27942 l OCTOBER JOGC OCTOBRE 2016Lidocaine is also a very safe drug. Also known as ligno-
caine, this agent has also been used systemically as an
antiarrhythmic and for treatment of neuropathic pain. Both
of these indications involve 1.0e1.5 mg/kg doses admin-
istered as an IV bolus or infusion.28 Toxicity results from
single doses greater than 300 mg (4.5 mg/kg without
epinephrine), and this far exceeds the 20 mg proposed for
combination with magnesium sulphate in the preﬁlled
syringe.29 Accidental intravascular injection of lidocaine
can lead to central nervous system and cardiovascular
intoxication, but the overall rate of adverse drug reactions
with lidocaine is low (0.01%).30 Nevertheless, care should
be taken to avoid inadvertent intravascular injection, by
aspiration prior to injection, by incremental injection, and
by dose limitation.31 The safety of lidocaine in pregnancy
has also been declared by the United States Food and Drug
Administration, which classiﬁes it as a category B drug.
This indicates that although there are no well controlled
studies in pregnant women, reproductive studies per-
formed revealed no evidence of harm to fetus,28 and it is
not contraindicated during labour and delivery. In fact, it is
listed as an option in the American Congress of Obste-
tricians and Gynecologists Practice Bulletin on appropriate
obstetric analgesia and anaesthesia.32
We believe that the ideal solution to encourage wider use of
magnesium sulphate would be to provide the active drug in
combination with lidocaine in a preﬁlled, ready-to-use
syringe for IM injection, easing both administration and
pain. Our study has shown that the combination of these
drugs can remain stable for up to six months.
Magnocaine: Physical Compatibility and Chemical Stability of MgSO4 and Lidocaine Hydrochloride in Preﬁlled SyringesUnfortunately, although the commercially available mag-
nesium sulphate remained stable in combination with
lidocaine, the reconstituted magnesium sulphate salt in
combination with commercially available lidocaine did not
retain 90% of its initial concentration in both storage
conditions at 168 days. The beneﬁt of reconstituting the
magnesium sulphate from salt was to enable a higher
concentration (61% vs. 50%), thereby reducing the volume
of injection from 10 mL to 8 mL. Even in the processing
phase, we had difﬁculty maintaining the higher concen-
tration in solution. Despite a solubility in water at 20C of
71 g/100 mL,33 mixtures containing more than 69 g/100
mL became cloudy. Interestingly, both the magnesium
sulphate reconstituted from salt alone and in combination
with commercial lidocaine was more stable at 168 days at
40C, which could be attributed to greater solubility at the
higher temperature. However, because of variable pro-
duction, conditions of transport, and storage temperature,
particularly in less-developed countries in which these
preﬁlled syringes would be most useful, the higher con-
centration would not likely remain in solution and would
thereby result in suboptimal doses.
Future research in a clinical trial with human subjects will
be required to determine the extent of the pain relief
provided by including lidocaine in the IM injection of
magnesium sulphate. Research is also ongoing to deter-
mine how to best use magnesium sulphate, including the
minimum effective dose and whether the initial dose can
safely be given before transfer to hospital.10 We hope these
ﬁndings will contribute to increased use of magnesium
sulphate and decreased maternal mortality and morbidity
related to preeclampsia and eclampsia.
CONCLUSION
The combination of commercially available magnesium
sulphate and lidocaine hydrochloride is physically and
chemically stable in a preﬁlled syringe for at least 168 days
at high heat and humidity. These ﬁndings make feasible
the concept of a preﬁlled “Magnocaine” syringe for IM
injection for the prevention and/or treatment of
eclampsia.
ACKNOWLEDGEMENTS
This project was funded by the Pre-eclampsiaeEclampsia
Monitoring, Prevention & Treatment Initiative, University
of British Columbia, a grant recipient of the Bill & Melinda
Gates Foundation.
Sara Houlihan wishes to acknowledge the inspiration of
her father, Richard Houlihan, who passed away in
December 2015. As a scientist, he understood the strugglesinvolved in conducting research; his sage advice and
encouragement will not be forgotten.
SUPPLEMENTARY DATASupplementary Data related to this article can be found
at http://dx.doi.org/10.1016/j.jogc.2016.04.097.REFERENCES
1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin
Perinatol 2009;33:130e7.
2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia.
Lancet 2010;376:631e44.
3. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis
of causes of maternal death: a systematic review. Lancet 2006;367:1066e74.
4. Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium
sulphate and other anticonvulsants for women with pre-eclampsia.
Cochrane Database Syst Rev 2010;(11):CD000025.
5. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do
women with pre-eclampsia, and their babies, beneﬁt from magnesium
sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet
2002;359:1877e90.
6. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women
with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet
1995;345:1455e63.
7. Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate
versus diazepam for eclampsia. Cochrane Database Syst Rev
2010;(12):CD000127.
8. Duley L, Henderson-Smart DJ, Chou D. Magnesium sulphate versus
phenytoin for eclampsia. Cochrane Database Syst Rev
2010;(10):CD000128.
9. Duley L, Gulmezoglu AM, Chou D. Magnesium sulphate versus lytic
cocktail for eclampsia. Cochrane Database Syst Rev 2010;(9):CD002960.
10. Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesium
sulphate regimens for women with pre-eclampsia and eclampsia.
Cochrane Database Syst Rev 2010;(8):CD007388.
11. Pritchard JA. The use of the magnesium ion in the management of
eclamptogenic toxemias. Surg Gynecol Obstet 1955;100:131e40.
12. Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial
Hospital protocol for treatment of eclampsia: evaluation of 245 cases.
Am J Obstet Gynecol 1984;148:951e63.
13. Zuspan FP. Problems encountered in the treatment of pregnancy-induced
hypertension. A point of view. Am J Obstet Gynecol 1978;131:591e7.
14. Liu S, Joseph KS, Liston RM, Bartholomew S, Walker M, Leon JA, et al.
Incidence, risk factors, and associated complications of eclampsia. Obstet
Gynecol 2011;118:987e94.
15. Newby B. Stability of magnesium sulfate 20% in viaﬂex bags. Can J Hosp
Pharm 2008;61:356e65.
16. Hagan RL, Carr-Lopez SM, Strickland JS. Stability of nafcillin sodium in the
presence of lidocaine hydrochloride. Am J Health Sys Pharmacy
1995;52:521e3.
17. Shaalan RA, Belal TS. HPLC-DAD stability indicating determination of
nitrofurazone and lidocaine hydrochloride in their combined topical
dosage form. J Chromatogr Sci 2010;48:647e53.
18. Souza JP, Gulmezoglu AM, Vogel J, Carroli G, Lumbiganon P, Qureshi Z,
et al. Moving beyond essential interventions for reduction of maternalOCTOBER JOGC OCTOBRE 2016 l 943
DRUGS IN PREGNANCYmortality (the WHO Multicountry Survey on Maternal and Newborn
Health): a cross-sectional study. Lancet 2013;381:1747e55.
19. Amir J, Ginat S, Cohen YH, Marcus TE, Keller N, Varsano I. Lidocaine as a
diluent for administration of benzathine penicillin G. Pediatr Infect Dis J
1998;17:890e3.
20. Patel IH, Weinfeld RE, Konikoff J, Parsonnet M. Pharmacokinetics and
tolerance of ceftriaxone in humans after single-dose intramuscular
administration in water and lidocaine diluents. Antimicrob Agents
Chemother 1982;21:957e62.
21. Hayward CJ, Nafziger AN, Kohlhepp SJ, Bertino JS Jr. Investigation of
bioequivalence and tolerability of intramuscular ceftriaxone injections by
using 1% lidocaine, buffered lidocaine, and sterile water diluents.
Antimicrob Agents Chemother 1996;40:485e7.
22. Schichor A, Bernstein B, Weinerman H, Fitzgerald J, Yordan E,
Schechter N. Lidocaine as a diluent for ceftriaxone in the treatment of
gonorrhea. Does it reduce the pain of the injection? Arch Pediatr Adolesc
Med 1994;148:72e5.
23. WHO Department of reproductive health and research Managing
complications in pregnancy and childbirth: a guide for midwives and
doctors. 2 ed. Geneva: WHO Press; 2007:S-45.
24. Tukur J. The use of magnesium sulphate for the treatment of severe pre-
eclampsia and eclampsia. Ann African Med 2009;8:76e80.
25. Sharma P, Mir S, Rizvi M, Akthar S. Efﬁcacy of magnesium sulphate versus
phenytoin in seizure control and prophylaxis in patients of eclampsia and
severe pre-eclampsia. JK Science 2008;10:181e5.944 l OCTOBER JOGC OCTOBRE 201626. Smith JM, Lowe RF, Fullerton J, Currie SM, Harris L, Felker-Kantor E. An
integrative review of the side effects related to the use of magnesium sulfate
for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth
2013;13:34.
27. McDonald SD, Lutsiv O, Dzaja N, Duley L. A systematic review of
maternal and infant outcomes following magnesium sulfate for pre-
eclampsia/eclampsia in real-world use. Int J Gynaecol Obstet
2012;118:90e6.
28. Lexicomp Online, Lexi-Drugs, Hudson, Ohio: Lexi-Comp, Inc.; July 7,
2013.
29. Sweetman SC. Martindale: the complete drug reference. 36 ed. London-
Chicago: Pharmaceutical Press; 2009.
30. Liu W, Yang X, Li C, Mo A. Adverse drug reactions to local anesthetics: a
systematic review. Oral Surg Oral Med Oral Path Oral Radiol
2013;115:319e27.
31. Mulroy MF. Systemic toxicity and cardiotoxicity from local anesthetics:
incidence and preventive measures. Regional anesthesia and pain
medicine 2002;27:556e61.
32. Goetzl LM. ACOG Practice Bulletin. Clinical Management Guidelines for
Obstetrician-Gynecologists, Number 36, July 2002. Obstetric analgesia
and anesthesia. Obstet Gynecol 2002;100:177e91.
33. MJ ON. Merck Index. 14 ed. New Jersey: Merck & Co. Inc; 2006.
Magnocaine: Physical Compatibility and Chemical Stability of MgSO4 and Lidocaine Hydrochloride in Preﬁlled SyringesAPPENDIX 1. Flow of Experimental and Control ProductsOCTOBER JOGC OCTOBRE 2016 l 944.e1
DRUGS IN PREGNANCYAPPENDIX 2. DETAILED METHODOLOGY9Chemistry Analyzer
MG reagentTM, used in conjunction with the SYNCHRON UniCel DxC600i system, determined the magnesium concentration of
each sample. In the reaction, MG reagentTM combines with calmagite to form stable chromogen. The product is formed rapidly
giving reproducible results with a minimum of interferences (known interferents include chelating agents such as EDTA/citrate/
oxalate, gadolinium and hemolysis given that erythrocytes contain magnesium). The system then monitors change in absorbance at
520 nanometers. This change in absorbance is directly proportional to the concentration of magnesium in the sample. Two levels of
assayed quality control were used to verify method performance. The method performance was based on monthly coefﬁcients of
variation (CVs). This method has a CV of 2.4% at a target concentration of 2.05 mmol/L and 1.2% at 4.92 mmol/L.
Preparation of magnesium reagent
The assay used to determine magnesium concentration with the UniCel DxC 600i Synchron Access clinical system has been
previously published.16 No preparation of the reagent was required as it was supplied by the manufacturer. The reagent used was
calibrated with the manufacturer’s calibrators prior to analysis. The magnesium in the calibrator is traceable to NIST SRM 929. (The
traceability process is based on prEN ISO 17511.) Commercially available magnesium sulphate 50% USP (PPC Pharmaceutical
Partners of Canada; Richmond Hill, Ontario; lot 6101127; expiry date June 2013) was used to as the internal control.
Preparation of the magnesium sulphate samples
Each magnesium sample (CM50CL2, CM50, MS, MSCL2) was thawed, vortex-mixed then diluted with sterile normal saline 1:1000
to meet the analytical range of the assay used. Final theoretical concentrations of magnesium sulphate were: 1844 mmol/L
(CM50CL2), 2029 mmol/L (CM50), 2475 mmol/L (MS), and 2205 mmol/L (MSCL2).
Degradation of Magnesium
Given that magnesium is a stable element, degradation is unlikely. However, to prove that there is no interference or cross-reactivity
between magnesium and lidocaine degradation products, magnesium-free solutions of commercially available lidocaine and normal
saline were analyzed by the Synchron. The samples of lidocaine were those stored up to 168 days as well as a commercially available
stock solution to assess for the interference of lidocaine degradation products. The second control with normal saline assessed for
leaching of magnesium from the polypropylene syringes. Finally, a standard addition of magnesium was also performed to observe
for a negative interference.
HPLC instrumentation15,16
The HPLC instrument (Waters Alliance System, model 2690; Waters Corporation; Mississauga ON) consists of a delivery pump, an
automatic injector equipped with a 200 mL injector a Symmetry C8 4.6  250 mm column (Waters Corporation; Mississauga ON;
lot 01843724213648), a Symmetry C8 3.9 20 mm guard column (Waters Corporation; Mississauga ON; lot 0184372211) and an
ultraviolet (UV) detector set at 234 nm. The mobile phase consisted of a mixture of 30% acetonitrile (Fisher Scientiﬁc; Whitby ON;
lot 126537) 70% ammonium formate buffer (Sigma-Aldrich; lot BCBG3990V) pH 3.0. The assay was performed at room tem-
perature. All solvents were HPLC-grade and ﬁltered before use. The ﬂow rate was set at 1.2 mL/min.
Preparation of lidocaine stock standard solutions
Lidocaine standards were prepared as follows. Lidocaine 20 mg/mL was diluted to 4 mg/mL in HPLC-grade water (Fisher
Scientiﬁc; Whitby ON; lot 127395). Dexamethasone powder 1 mg/mL (Sigma-Aldrich; Oakville ON; lot 120M1331V) diluted in
HPLC-grade water was selected as IS. Lidocaine standard solutions containing 0.25 mg/mL of the IS were prepared in HPLC-
grade water to ﬁnal concentrations of 0.100, 0.200, 0.300, 0.500, 0.700, and 0.800 mg/mL. In order to prevent injection of im-
purities onto the column, all standards were ﬁltered through a GHP (Gelman hydrophobic polyethylene) 13 mm diameter, 0.45 mm
microﬁlter AcrodiscTM (Waters Corporation; Mississauga ON; lot 21770796) prior to injection.44.e2 l OCTOBER JOGC OCTOBRE 2016
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A 6-point calibration curve was prepared with a blank (water) at the beginning of each run to ensure that there is no carry-over
between runs. The range of the standard curve (0.100e0.800 mg/mL) encompassed the diluted test concentrations of all the study
solutions. The calibration curve was generated by the least square regression of the peak area ratio of lidocaine to dexamethasone
and the concentration of each lidocaine standard.
The precision of the assay was evaluated by intra-day and inter-day validation methods. Intra-day validation was determined by
running the standard’s lower limit of quantitation, low, medium, and high concentrations (0.100, 0.250, 0.400, 0.600 mg/mL) in
quadruplicate throughout a single day. The inter-day validation was determined by running the same standard concentrations in
quadruplicate daily for 4 days. Accuracy of the assay was calculated as the mean deviation between nominal and observed con-
centrations. Mean, standard deviation, and coefﬁcient of variation were also calculated. Acceptable limits of coefﬁcients of variation
for precision were deﬁned a priori as less than 10% and acceptable limits for accuracy were deﬁned as greater than 90%.
Preparation of lidocaine samples
Each lidocaine study sample (CL2, MSCL2, and CM50CL2) was thawed and then vortex-mixed for 10 seconds. The CL2 sample
was diluted 10-fold with HPLC-grade water. A 0.250 mL of either the diluted CL2 sample or the MSCL2 and CM50CL2 sample
was added to 0.250 mL of IS and 0.500 mL of HPLC-water for ﬁnal theoretical concentrations of 0.50 mg/mL CL2, 0.454 mg/mL
MSCL2, 0.544 mg/mL CM50CL2, and 0.250 mg/mL IS. Each sample was ﬁltered through a 0.45 mm AcrodiscTM microﬁlter
before a 25 mL was injected onto the column.
Degradation of lidocaine
Sets of 1 mL CL2 (1:10), CM50CL2, and MSCL2 samples were treated with 500 mL of either 1N NaOH, 1N HCl, or 30% H2O2
and water as control and then vortex-mixed. A set of solutions was kept at room temperature and the remaining samples were
placed in a water bath at 100C for 2 hours. The controls were kept at room temperature. Both sets of samples and the controls
were stored protected from UV light. After the speciﬁc period, the samples were placed at 4C overnight. They were then allowed
to warm up to room temperature and were neutralized and the ﬁnal volume was adjusted to 2 mL. The aliquots were then diluted
1:2 in water without internal standard. The samples were ﬁltered and injected onto the column. The chromatograms obtained were
compared to a chromatogram obtained from the calibration curve to determine any changes in concentration, retention time, and
peak shape.OCTOBER JOGC OCTOBRE 2016 l 944.e3
